CCT007093

inhibits the p53 inducible phosphatase Wip1

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Breast Neoplasms (Breast Cancer) 02/01/2014 - "Of note, CCT007093 treatment appeared to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression. " 01/01/2010 - "When chemical inhibitors, CCT007093 and mithramycin, against two top hits in our screen, PPMID and SP1, respectively, were used in combination with paclitaxel, we observed synergistic growth inhibition in both 2D and 3D breast cancer cell cultures. "
2.	Medulloblastoma 04/01/2012 - "Knockdown of WIP1 or treatment with the WIP1 inhibitor CCT007093 results in increased phosphorylation of known WIP1 targets, reduced HDM2 expression, and reduced growth specifically in WIP1 wild-type and high-expressing medulloblastoma cells. "